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ESSENTIALS 
• The once-daily dosing of tinzaparin provides an advantage over other low molecular weight 
heparins.  
• The recommended age-dependent doses of tinzaparin in children have not previously been 
validated. 
• Once-daily administration of tinzaparin is a safe and effective treatment of childhood 
thrombosis. 
• Recommended doses are appropriate but monitoring may be required due to inter-individual 
variation. 
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ABSTRACT  
Background 
Recommended starting doses of tinzaparin for the treatment of thrombosis in children have not 
previously been validated. There are few data to support efficacy and safety of once-daily tinzaparin 
dosing in children with thrombosis. 
Objectives 
This study investigated using tinzaparin for the treatment of childhood thrombosis.  It aimed to 
evaluate the age-dependent dosing recommendations and to define outcomes in terms of efficacy and 
safety. 
Methods 
This was a retrospective cohort study of children aged 0-<16 years treated for thrombosis at a large 
teaching hospital in the United Kingdom between 2008 and 2015.   Medical records were reviewed to 
evaluate tinzaparin dosing, anti-factor Xa levels and patient outcomes.  
Results 
79 children were identified to have received tinzaparin. Dosing information was available for 57. 
Younger children required higher doses to reach a therapeutic level. Therapeutic dose requirement 
varied within age groups, supporting the use of anti-factor Xa monitoring.  Over a median follow up 
of 35 months, there were 13 (16%) bleeding episodes (2 major; 7 clinically relevant but non-major; 4 
minor).  There were 2 (3%) recurrent episodes of thrombosis.  Children were treated for a median 
duration of 3 months and the majority (86%) remained on tinzaparin for the duration of their 
anticoagulant therapy. 
Conclusion 
Once-daily tinzaparin is a safe and effective treatment of childhood thrombosis with rates of 
recurrence and bleeding similar to other anticoagulants used in children. The recommended starting 
doses are appropriate but anti-factor Xa monitoring may be required due to inter-individual variability 
in the therapeutic dose requirement. 
 
KEYWORDS: Anticoagulants; Heparin low-molecular-weight; Pediatrics; Tinzaparin; Thrombosis 
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INTRODUCTION 
Due to difficulties in the administration of oral coumarins, childhood thrombosis is frequently treated 
with low molecular weight heparin (LMWH) (1, 2).  In comparison to other preparations, which use a 
twice-daily dosing regimen, tinzaparin has the advantage of once-daily administration. 
 
Current age-dependent dosing recommendations for tinzaparin are based on a single study of 35 
children with small numbers in each age group: 0-2 month age group included 10 children; 2-12 
years, 8; 1-5 years, 6; 5-10 years, 4; and 10-16 years, 7. Individuals were followed up for a relatively 
short period of time, either 3 months or until they completed anticoagulation (whichever was sooner), 
providing data for a median follow up of 3 months (3).   These data have not been validated in an 
independent cohort. 
 
This study aimed to determine whether the recommended age-dependent starting doses are 
appropriate to achieve therapeutic anticoagulation in a timely manner.  A secondary aim was to assess 
safety and efficacy of once-daily tinzaparin for the treatment of childhood thrombosis. 
 
 
METHODS 
Patient selection 
Consecutive children who were anticoagulated with tinzaparin at the Newcastle upon Tyne Hospitals 
NHS Foundation Trust between January 2008 and October 2010 were identified retrospectively from 
a hospital database.  Children aged 0 to <16 years were included.  All were treated with once-daily 
tinzaparin with the aim of achieving therapeutic anticoagulation. Although the majority of children 
were treated for a thrombotic event, either venous or arterial, children who required therapeutic 
anticoagulation for other indications were also eligible for inclusion.  
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Dosing and monitoring of tinzaparin 
The institutional recommendation for initial tinzaparin dosing was based on the age-dependent 
recommendations made by Kuhle et al. and published in the American College of Chest Physicians 
(ACCP) guidelines: age 0-<2 months, initial dose 275 U/kg; 2-<12 months, 250 U/kg; 1-<5 years, 240 
U/kg; 5-<10 years, 200 U/kg; and 10-<16 years, 175 U/kg (3, 4). 
 
It was recommended that peak anti-factor Xa activity was measured 3 hours after administration of 
the second dose. Anti-factor Xa activity was measured using the automated coagulation analyser ACL 
TOP® CTS (Instrumentation Laboratory, Lexington, MA, USA) and anti-factor Xa reagents obtained 
from Instrumentation Laboratory (Bedford, MA 01730, USA).  The assay uses endogenous 
antithrombin, and dextran sulphate is included in the reaction mixture to reduce the influence from 
heparin antagonists such as platelet factor 4.  The dose of tinzaparin was adjusted by increments of 
10-20% to achieve and maintain anti-factor Xa activity within the therapeutic range.  An anti-factor 
Xa activity of 0.5-1.0 IU/mL was considered to be therapeutic. Once therapeutic levels had been 
reached, anti-factor Xa activity was not tested routinely unless clinically indicated. 
 
Collection of outcome data 
Medical notes and imaging records were reviewed for details regarding site of thrombosis, duration of 
anticoagulant therapy, thrombus resolution, recurrent thrombosis, bleeding episodes and long-term 
consequences including post-thrombotic syndrome.  Bleeding was classified according to 
International Society on Thrombosis and Haemostasis (ISTH) criteria: major (fatal bleeding, a 
decrease in haemoglobin ≥ 20g/L in 24 hours, bleeding that is 
retroperitoneal/pulmonary/intracranial/involves the central nervous system or requires surgical 
intervention in an operating suite); clinically-significant non-major (need for blood product 
transfusion or intervention not in an operating suite); or minor (bleeding that does not fulfil the above 
criteria, including menstrual bleeding requiring a medical consultation) (5). 
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Statistics 
Minitab software was used to analyse the data.  Log transformation of therapeutic dose was performed 
and square root of duration to therapeutic dose was calculated, in order to approximately normalise 
the data. The values were compared between the 5 age groups using a one-way ANOVA. Tukey’s 
multiple comparison procedure was then used to identify which groups were different at a nominal p-
value <0.05. T-tests were used for post-hoc contrasts. The proportions of children whose starting dose 
was within 10U/kg of the recommended dose were compared between age groups using Chi-sqaure 
tests. Levene’s test was used to compared the within group variability between age groups.   
 
RESULTS 
79 cases were identified, 48 (61%) of which were male.  The median age was 3 years (range: 0-15) 
and the number of children within each age range was as follows:  0-<2 months, 9 cases; 2-<12 
months, 14; 1-<5 years, 23; 5-<10 years, 9; 10-<16 years, 24.   Median follow up was 36 months 
(range: 1 - 117).   
 
Site of thrombosis 
The most frequent sites of thrombosis were lower limb deep vein thrombosis (DVT) and cerebral 
venous sinus thrombosis (see Table 1). 13 individuals had thrombosis in multiple locations and 34 
thrombotic events were related to a central venous access device (CVAD).  One case did not have a 
thrombosis but required therapeutic anticoagulation as thromboprophylaxis for a vertebral artery 
dissection. At least one identifiable provoking factor was present in the majority of cases (97%). 
 
Initial and maintenance tinzaparin dosing 
Data on tinzaparin dosing were analysed for 57 cases.  The remaining individuals were excluded from 
the analysis for the following reasons: 6 who received twice-daily dosing of tinzaparin at initiation of 
anticoagulant therapy, 15 for whom there were insufficient dosing data and 1 who had severe renal 
impairment (in this case 75% of the recommended dose was given).  In those who received twice-
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daily dosing, the recommended daily dose was halved and administered in two injections 12 hours 
apart.  This was done in cases where clinicians perceived a higher than normal risk of bleeding. 
 
Overall, 30/57 (53%) started treatment within 10 U/kg of the recommended initial dose. The 
proportion in each age group that started treatment within 10 U/kg of the recommended dose was: 0-2 
months, 33%; 2-12 months, 0%; 1-5 years, 63%; 5-10 years, 56%; 10-16 years, 62%, (p=0.05).  
Compared to older children, those aged <12 months were less likely to be started within 10U/kg of the 
recommended dose (25% versus 61%, p = 0.006).  The younger children were more likely to be 
initiated on a dose lower than recommended. Therapeutic anti-factor Xa levels were achieved in 55 
cases (96%) and, of the 2 cases that did not reach a therapeutic level, 1 had a starting dose 100 U/kg 
lower than recommended. Table 2 shows the median starting dose for each age group and the dose at 
which therapeutic anticoagulation was achieved.  Analysis of log therapeutic dose per body weight by 
age group gave a p value of <0.001 (R-squared = 37%), denoting significant differences. However the 
three youngest age groups and the two oldest age groups did not differ significantly in mean value. 
Combining the three youngest age groups and the two oldest age groups gave a difference in log 
therapeutic dose of 0.29 (95%CI (0.19, 0.39), p<0.001). Transforming back to the original scale gave 
average values of 275 U/kg in the three youngest groups compared to 205 U/kg in the two oldest 
groups.   
 
 
The median time to achieve therapeutic anticoagulation was 4 days (range: 1-29 days).  There was no 
significant difference in the number of days to reach therapeutic anticoagulation between age groups 
(p=0.32).  There was also no significant difference in the number of days to reach therapeutic 
anticoagulation between those who started >10 U/kg outside of the recommended dose and those who 
started ≤10 U/kg (p = 0.54). 
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Figure 1 shows the inter-individual variability in the dose of tinzaparin that was required to achieve 
therapeutic anticoagulation within each age group. However, there was no significant difference in the 
variability of therapeutic dose per kg between age groups (p=0.47).  
 
Children were anticoagulated for a median of 3 months (range: 2 days - 9 months).  22 (28%) 
individuals continued treatment beyond 3 months, 50% of whom continued tinzaparin. 
Anticoagulation was continued long term in 8 cases: 4 with tinzaparin, 3 with warfarin and 1 with 
rivaroxaban. Two individuals treated for ≤ 3 months were converted to warfarin. 
 
Outcomes 
Median follow-up was 35 months (range: 1-117 months).  3 cases were lost to follow-up.  There were 
3 deaths during the follow-up period (4%). No deaths were attributable to the thrombotic event or 
complications of anticoagulant therapy. 
 
Bleeding complications were recorded in 10 cases (13%).  There was a total of 13 (16%) bleeding 
episodes with 3 individuals experiencing more than.  Bleeding sites included: CVAD site, 3; 
haematuria, 3; rectal, 2; intra-cranial haemorrhage, 1; pulmonary haemorrhage, 1; menorrhagia, 1; 
epistaxis, 1; and Insuflon site, 1.  In 5 individuals, the anti-factor Xa level was sub-therapeutic at the 
time of the bleeding episode and in 5 it was not measured.  There were no episodes of bleeding 
associated with known therapeutic or supra-therapeutic levels. Using ISTH criteria, there were 2 
major bleeds (intra-cranial haemorrhage and pulmonary haemorrhage), 7 clinically relevant non-major 
bleeds and 4 minor bleeds.  All bleeding complications occurred within 7 months of starting treatment 
and 4 within 1 month.  Interventions required for bleeding were: missed dose of tinzaparin, 2; 
reduction to prophylactic dose of tinzaparin (75 U/kg daily), 1; blood transfusion, 1; nasal packing for 
epistaxis, 1.  
 
There were two episodes of recurrent thrombosis (3%).  1 individual with intra-cardiac thrombus 
developed a further arterial thrombus 17 days after commencing anticoagulant therapy and a week 
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later developed a PE during a surgical thrombectomy.  This case started with a lower than 
recommended initiation dose but achieved therapeutic anticoagulation within 1 day.  The second 
occurred 3 months after starting treatment for a CVAD-related neck vein thrombosis, at a time when 
anti-factor Xa activity levels were sub-therapeutic. 
 
42 individuals developed thrombosis in an extremity or the vena cava.  7/42 (17%) had clinical signs 
of post-thrombotic syndrome but all were asymptomatic:  3 cases of upper limb DVT had superficial 
venous distension of the upper limb or chest wall, one of whom also had disparity of upper arm 
circumference; 4 with lower limb DVT had >1cm disparity of thigh circumference.  
 
DISCUSSION 
These data support the current age-dependent dosing recommendations for tinzaparin in the 
therapeutic anticoagulation of children <16 years of age (3, 4). In both our cohort and that reported by 
Kuhle et al., 97% of children achieved therapeutic levels of tinzaparin using this approach (3).  Kuhle 
et al. reported a marginally shorter median time for therapeutic anticoagulation to be achieved (2 
days) than in our cohort (4 days), most likely due to the measurement of anti-factor Xa activity only 
when clinically indicated in our cohort (3). Younger children required higher weight-adjusted doses 
than older children, similar to other LMWHs (2). There was inter-individual variability in the dose of 
tinzaparin that was required to achieve therapeutic anticoagulation within each age group, as has been 
shown in previous paediatric studies of LMWHs (3, 6-11), supporting the need to monitor using anti-
factor Xa activity levels. Contrary to other studies, this variability was no greater within the younger 
age groups when compared to the older age groups (2, 3).  Previous work has also demonstrated that 
whilst children younger than 5 years eliminate tinzaparin faster and require higher doses, they also 
tend to reach peak drug levels faster than older children (2, 3). A recent review of tinzaparin dosing in 
a paediatric intensive care unit showed that higher than recommended doses were required in this 
particular clinical setting and again supported the need for anti-factor Xa activity monitoring (12).  
Tinzaparin has been shown to have a higher level of anti-IIa activity compared to other LMWHs such 
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as enoxaparin (13).  Previous work involving unfractionated heparin demonstrated that anti-IIa 
activity can be affected by age, with the differences being more pronounced in younger children (14).  
 
There were no deaths related to thrombosis or anticoagulant therapy in our cohort. The relatively low 
mortality rate, compared to previous published cohorts of children with thrombosis, may be due to 
bias in relation to the choice of anticoagulant: unfractionated heparin is used in preference to LMWH 
in our institution for complex, often post-surgical, cases and these individuals may be at greater risk 
of death. The previous study by Kuhle et al. reported a similar rate of major bleeding (3%) to our 
cohort, defined as a drop in haemoglobin of ≥ 20g/L over 24hrs, the need for red cell transfusion, or 
critical site bleeding (retroperitoneal, intracranial, intraocular or intra-articular). Kuhle et al. reported 
a higher rate of thromboembolic recurrence (11%) although all recurrences occurred at a sub-
therapeutic level of anticoagulation (3).  The recurrence rate was comparably low in our cohort (3%), 
potentially due to the retrospective nature of the study and the lack of routine follow-up imaging.  As 
is usually the case in children with thrombosis, the majority of events were ‘provoked’: this may also 
explain the low rate of recurrence in this study.   A systematic review of LMWH use in children found 
similarly low rates of major bleeding and symptomatic recurrence to our cohort (15). A recent study 
investigated the use of tinzaparin in children who had developed CVAD-related thrombus whilst 
undergoing regular haemodialysis.  Ten individuals, aged between 7 months and 15 years, were 
identified, and starting dose was not adjusted for age.  There were no episodes of bleeding, but a 
higher rate of recurrence (10%), which may be explained by the necessity to maintain central venous 
access (14). Other studies have confirmed the efficacy and safety of other LMWHs, such as 
enoxaparin and dalteparin (10, 11, 17, 18).  Tousovska et al. investigated the use of enoxaparin in 33 
children undergoing cancer treatment. Despite the majority of cases experiencing thrombocytopenia, 
with a platelet count of <20 x 109/L, during treatment with enoxaparin there were no cases of severe 
bleeding (19).  
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Prospective randomised controlled trials of anticoagulants are difficult to complete in the paediatric 
population due to the relatively low frequency of thrombosis.  The first multi-centre randomised 
controlled trial of treatment of venous thromboembolism in children compared the LMWH reviparin 
to unfractionated heparin and vitamin K antagonists.  It closed early due to poor recruitment but 
supported reviparin as an effective and safe treatment (20).  The current multi-centre Kids-DOTT 
trial, the primary aim of which is to investigate shortened duration of anticoagulation following 
venous thromboembolism in children, reported pilot/feasibility data after recruiting the first 100 
participants.  The majority were treated with LMWH, and rates of symptomatic recurrence and 
clinically significant bleeding at 1 year of follow-up were 3.3% and 1.4%, respectively, again similar 
to this cohort (21).  Other studies investigating the use of direct oral anticoagulants, such as 
Dabigatran and Rivaroxaban, use LMWH as one of the ‘standard of care’ comparators 
[ClincalTrials.gov NCT01895777; NCT02234843] and will hopefully add to our knowledge of the 
efficacy and safety of LMWH in the treatment of childhood thrombosis. Our data support a once-daily 
tinzaparin regimen as safe and effective treatment for childhood thrombosis.  We would suggest 
monitoring of anti-factor Xa levels 2 doses following both initiation of therapy and a change of dose. 
 
In terms of limitations, this was a retrospective cohort study that was limited to the use of the LMWH 
tinzaparin. In this cohort, anti-factor Xa activity levels were not routinely measured immediately 
following dose increments, limiting our ability to accurately measure the time taken to achieve 
therapeutic anticoagulation. This was likely to have been over-estimated as only 46% of the cohort 
initiated tinzaparin within 10 U/kg of the recommended dosage. A further limitation concerns how the 
tinzaparin was administered.  Both pre-filled syringes and vials were used, which may have altered 
the decisions made about dose increments.  Within our institute, Insuflons are often used in children 
with weight >5kg but in other cases daily injections are used: the presence of ‘dead space’ within the 
Insuflon may have had an impact on anti-factor Xa activity levels. In addition, previous studies have 
questioned the utility of anti-factor Xa activity monitoring for predicting efficacy and safety of 
LMWH therapy in children (22).  Previous work suggests that the addition of dextran sulphate to the 
anti-factor Xa activity assay used in this cohort may have exaggerated anti-Xa activity (23). 
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A prospective study of tinzaparin use for the management of thrombosis in the paediatric population 
is required.  In addition to recording rates of recurrence and bleeding episodes, it would be helpful to 
evaluate: the response to treatment as assessed by follow up imaging at defined timepoints; the 
incidence of post-thrombotic syndrome measured using a validated scoring system; and an analysis of 
the impact of once-daily dosing on quality of life and cost. 
  
CONCLUSION 
Tinzaparin is safe and effective treatment for childhood thrombosis. Younger patients require higher 
doses per kg body weight.  Due to variability in response between individuals of a similar age, 
monitoring of anti-factor Xa activity levels is required in order to ensure that therapeutic 
anticoagulation is achieved.  
Addendum 
The research was designed and performed by K. Webber, P. Murphy, K. Musgrave, and T. 
Biss. Data analysis was performed by K Musgrave and P Avery. The paper was written by K 
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Site of Thrombosis Number 
of cases 
Lower limb DVT 25
Cerebral venous sinus thrombosis 16
Upper limb/neck DVT 14
Intra-cardiac 13
IVC 11
PE 8
SVC 4
Lower limb arterial thrombosis 3
Aortic thrombus 2
Portal vein 1
 
Table 1: Site of thrombosis in 78 children who received therapeutic anticoagulation with tinzaparin  
DVT – deep vein thrombosis, CVST – cerebral venous sinus thrombosis, IVC – inferior vena cava, PE 
– pulmonary embolism, SVC – superior vena cava. 
 
 
 
Age 
Number in 
each age 
range 
Recommended 
initial 
tinzaparin 
dose, U/kg 
Median initial 
tinzaparin dose, 
U/kg (range)  
Median dose of 
tinzaparin required 
to achieve 
therapeutic 
anticoagulation, U/kg 
(range) 
0 - < 2 months 9 275 250 (100 - 357) 275 (210 - 386) 
2 - < 12 months 6 250 266.5 (200 - 426) 267 (200 - 426) 
1 - < 5 years 15 240 239 (142 - 250) 271 (180 - 356) 
5 - < 10 years 8 200 200 (100 - 205) 200 (169 - 316) 
10 - < 16 years 19 175 175 (109 - 207) 186 (169 - 292) 
 
Table 2: Median initial daily tinzaparin dose and dose required to achieve therapeutic  
anticoagulation in 57 children   
U/kg- units per kilogram 
 
Figure 1 
Once daily tinzaparin dose required to achieve therapeutic anticoagulation 
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